DMAA (Drugs Made In America Acquisition) Loans Receivable: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DMAA Drugs Made In America Acquisition Corp DMAA
14 GF Score
Price $10.70
! 1 Warning Sign
View Full Analysis

What is Drugs Made In America Acquisition Loans Receivable?

Drugs Made In America Acquisition DMAA +0.09% 14 Loans Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates DMAA with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

Drugs Made In America Acquisition's Loans Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Drugs Made In America Acquisition Loans Receivable Related Terms

Drugs Made In America Acquisition Loans Receivable Historical Data

* Premium members only.

The historical data trend for Drugs Made In America Acquisition's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Drugs Made In America Acquisition Loans Receivable Chart

Drugs Made In America Acquisition Annual Data
Trend Dec24 Dec25
Loans Receivable
0.00 0.00

Drugs Made In America Acquisition Quarterly Data
Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Loans Receivable Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
DMAA
14GF Score
Drugs Made In America Acquisition Corp DMAA
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Drugs Made In America Acquisition Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0.00 Mil mean?
Drugs Made In America Acquisition (DMAA) has a Loans Receivable of $0.00 Mil as of Mar. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Drugs Made In America Acquisition and its competitors.
Is Drugs Made In America Acquisition's Loans Receivable too high?
Drugs Made In America Acquisition's current Loans Receivable is $0.00 Mil. Overall, Drugs Made In America Acquisition has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Drugs Made In America Acquisition's Loans Receivable compare to PLMK and TRGS?
Drugs Made In America Acquisition's Loans Receivable of $0.00 Mil can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Diversified Financial Services company?
A good Loans Receivable depends on the Diversified Financial Services industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Drugs Made In America Acquisition and its competitors. Drugs Made In America Acquisition's current Loans Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Drugs Made In America Acquisition stock overvalued right now?
Drugs Made In America Acquisition (DMAA) has a current Loans Receivable of $0.00 Mil. The current Loans Receivable is $0.00 Mil. Drugs Made In America Acquisition's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Drugs Made In America Acquisition (DMAA), the current Loans Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Drugs Made In America Acquisition Business Description

Address 420 Lexington Avenue, Suite 1402, New York, NY, USA, 10170
Drugs Made In America Acquisition Corp is a blank check company.
14GF Score

Get the complete analysis for DMAA

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.70
Price